[Form 3] West Pharmaceutical Services, Inc. Initial Statement of Beneficial Ownership
Robert W. McMahon, the company's SVP & Chief Financial Officer, reported an initial beneficial ownership position in West Pharmaceutical Services (WST). He directly holds restricted stock units of 3,168 and 12,670 shares, and two stock options covering 7,647 and 7,137 shares with an exercise price of $240.33. The options become exercisable on 08/11/2026 and expire on 08/11/2035. In total the reported awards underlie 30,622 common shares and are reported as direct beneficial ownership.
Robert W. McMahon, il SVP e Chief Financial Officer della societ脿, ha dichiarato una posizione iniziale di propriet脿 beneficiaria in West Pharmaceutical Services (WST). Detiene direttamente unit脿 di azioni vincolate per 3,168 e 12,670 azioni e due opzioni su azioni relative a 7,647 e 7,137 azioni con prezzo di esercizio di $240.33. Le opzioni diventano esercitabili il 08/11/2026 e scadono il 08/11/2035. In totale, i premi dichiarati sottendono 30,622 azioni ordinarie e sono registrati come propriet脿 beneficiaria diretta.
Robert W. McMahon, el SVP y Chief Financial Officer de la compa帽铆a, inform贸 una posici贸n inicial de propiedad beneficiaria en West Pharmaceutical Services (WST). Posee directamente unidades de acciones restringidas por 3,168 y 12,670 acciones, y dos opciones sobre acciones correspondientes a 7,647 y 7,137 acciones con un precio de ejercicio de $240.33. Las opciones se vuelven ejercitables el 08/11/2026 y vencen el 08/11/2035. En total, las adjudicaciones reportadas abarcan 30,622 acciones ordinarias y se registran como propiedad beneficiaria directa.
Robert W. McMahon鞚� 須岇偓鞚� SVP 瓴� 斓滉碃鞛毂呾瀯鞛�搿滌劀 West Pharmaceutical Services(WST)鞐� 雽�頃� 齑堦赴 靾橃澋 靻岇湢 歆�攵勳潉 鞁犼碃頄堨姷雼堧嫟. 攴鸽姅 歆侅爲鞝侅溂搿� 鞝滍暅欤检嫕雼渼 3,168欤� 氚� 12,670欤茧ゼ 氤挫湢頃橁碃 鞛堨溂氅�, 頄夓偓臧�瓴╈澊 $240.33鞚� 7,647欤� 氚� 7,137欤检棎 雽�頃� 霊� 瓯挫潣 鞀ろ啞鞓奠厴鞚� 氤挫湢頃橁碃 鞛堨姷雼堧嫟. 鞓奠厴鞚� 08/11/2026鞐� 頄夓偓 臧�電ロ暣歆�氅� 08/11/2035鞐� 毵岆霅╇媹雼�. 氤搓碃霅� 氤挫儊鞚� 齑� 30,622 氤错喌欤检棎 頃措嫻頃橂┌ 歆侅爲鞝� 靾橃澋 靻岇湢搿� 鞁犼碃霅橃棃鞀惦媹雼�.
Robert W. McMahon, SVP et directeur financier de l'entreprise, a d茅clar茅 une position initiale de propri茅t茅 b茅n茅ficiaire dans West Pharmaceutical Services (WST). Il d茅tient directement des unit茅s d'actions restreintes de 3,168 et 12,670 actions, ainsi que deux options sur actions couvrant 7,647 et 7,137 actions avec un prix d'exercice de $240.33. Les options deviennent exer莽ables le 08/11/2026 et expirent le 08/11/2035. Au total, les attributions d茅clar茅es sous-tendent 30,622 actions ordinaires et sont d茅clar茅es comme propri茅t茅 b茅n茅ficiaire directe.
Robert W. McMahon, der SVP und Chief Financial Officer des Unternehmens, meldete eine anf盲ngliche wirtschaftliche Eigent眉merposition in West Pharmaceutical Services (WST). Er h盲lt direkt Restricted Stock Units in H枚he von 3,168 und 12,670 Aktien sowie zwei Aktienoptionen 眉ber 7,647 und 7,137 Aktien mit einem Aus眉bungspreis von $240.33. Die Optionen werden am 08/11/2026 aus眉bbar und verfallen am 08/11/2035. Insgesamt beziehen sich die gemeldeten Zuwendungen auf 30,622 Stammaktien und werden als direktes wirtschaftliches Eigentum angegeben.
- None.
- None.
Insights
TL;DR: Routine Section 16 disclosure showing executive equity awards totaling 30,622 underlying shares; no unusual terms.
The filing documents typical equity compensation for a senior executive: two restricted stock unit grants and two stock options. The options carry an exercise price of $240.33 and long-dated expirations to 2035, with exercisability beginning in 2026. This is a standard reporting of direct holdings under Section 16 and, on its face, does not signal material corporate or market-moving events.
TL;DR: Standard governance disclosure that records direct equity-linked incentives for a senior officer; procedural and non-material.
The Form 3 records direct ownership of RSUs and options by the SVP & CFO, consistent with routine executive compensation practices and required insider reporting. Vesting schedules and exercisability are disclosed for transparency. The disclosure itself is governance-compliant and does not indicate departures, transfers, or unusual governance actions.
Robert W. McMahon, il SVP e Chief Financial Officer della societ脿, ha dichiarato una posizione iniziale di propriet脿 beneficiaria in West Pharmaceutical Services (WST). Detiene direttamente unit脿 di azioni vincolate per 3,168 e 12,670 azioni e due opzioni su azioni relative a 7,647 e 7,137 azioni con prezzo di esercizio di $240.33. Le opzioni diventano esercitabili il 08/11/2026 e scadono il 08/11/2035. In totale, i premi dichiarati sottendono 30,622 azioni ordinarie e sono registrati come propriet脿 beneficiaria diretta.
Robert W. McMahon, el SVP y Chief Financial Officer de la compa帽铆a, inform贸 una posici贸n inicial de propiedad beneficiaria en West Pharmaceutical Services (WST). Posee directamente unidades de acciones restringidas por 3,168 y 12,670 acciones, y dos opciones sobre acciones correspondientes a 7,647 y 7,137 acciones con un precio de ejercicio de $240.33. Las opciones se vuelven ejercitables el 08/11/2026 y vencen el 08/11/2035. En total, las adjudicaciones reportadas abarcan 30,622 acciones ordinarias y se registran como propiedad beneficiaria directa.
Robert W. McMahon鞚� 須岇偓鞚� SVP 瓴� 斓滉碃鞛毂呾瀯鞛�搿滌劀 West Pharmaceutical Services(WST)鞐� 雽�頃� 齑堦赴 靾橃澋 靻岇湢 歆�攵勳潉 鞁犼碃頄堨姷雼堧嫟. 攴鸽姅 歆侅爲鞝侅溂搿� 鞝滍暅欤检嫕雼渼 3,168欤� 氚� 12,670欤茧ゼ 氤挫湢頃橁碃 鞛堨溂氅�, 頄夓偓臧�瓴╈澊 $240.33鞚� 7,647欤� 氚� 7,137欤检棎 雽�頃� 霊� 瓯挫潣 鞀ろ啞鞓奠厴鞚� 氤挫湢頃橁碃 鞛堨姷雼堧嫟. 鞓奠厴鞚� 08/11/2026鞐� 頄夓偓 臧�電ロ暣歆�氅� 08/11/2035鞐� 毵岆霅╇媹雼�. 氤搓碃霅� 氤挫儊鞚� 齑� 30,622 氤错喌欤检棎 頃措嫻頃橂┌ 歆侅爲鞝� 靾橃澋 靻岇湢搿� 鞁犼碃霅橃棃鞀惦媹雼�.
Robert W. McMahon, SVP et directeur financier de l'entreprise, a d茅clar茅 une position initiale de propri茅t茅 b茅n茅ficiaire dans West Pharmaceutical Services (WST). Il d茅tient directement des unit茅s d'actions restreintes de 3,168 et 12,670 actions, ainsi que deux options sur actions couvrant 7,647 et 7,137 actions avec un prix d'exercice de $240.33. Les options deviennent exer莽ables le 08/11/2026 et expirent le 08/11/2035. Au total, les attributions d茅clar茅es sous-tendent 30,622 actions ordinaires et sont d茅clar茅es comme propri茅t茅 b茅n茅ficiaire directe.
Robert W. McMahon, der SVP und Chief Financial Officer des Unternehmens, meldete eine anf盲ngliche wirtschaftliche Eigent眉merposition in West Pharmaceutical Services (WST). Er h盲lt direkt Restricted Stock Units in H枚he von 3,168 und 12,670 Aktien sowie zwei Aktienoptionen 眉ber 7,647 und 7,137 Aktien mit einem Aus眉bungspreis von $240.33. Die Optionen werden am 08/11/2026 aus眉bbar und verfallen am 08/11/2035. Insgesamt beziehen sich die gemeldeten Zuwendungen auf 30,622 Stammaktien und werden als direktes wirtschaftliches Eigentum angegeben.
FAQ
What did Robert W. McMahon disclose on the Form 3 for WST?
How many total shares underlie McMahon's reported awards?
What is the exercise price and term of the reported stock options?
Are the reported holdings direct or indirect?
What is McMahon's role at West Pharmaceutical (WST)?
